SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Bispecific Antibodies: Clinical Trial Tracker

[February 21, 2014]

Research and Markets: Bispecific Antibodies: Clinical Trial Tracker

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/v9bn9s/bispecific) has announced the addition of the "Bispecific Antibodies: Clinical Trial Tracker" report to their offering.

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.

Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system.

As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases.

The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjuates. A number of such trials which are taking place for a variety of indications across multiple geographies have been identified.


The information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

Detailed forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders

Key Topics Covered:

I. Introduction and Pipeline Details

Section 1: Market Overview

Section 2: Dashboard: Pipeline Analysis

Section 3: Molecules in Clinical Development: Trial Details

Section 4: Molecules in Preclinical Development: Trial Details

Section 5: Inclusion / Exclusion Criteria

II Market Forecast, 2013 - 2023

Section 6: Market Forecast: Assumptions

Section 7: Market Forecast: Details

Section 8: Comparative Forecast Scenarios

III. Industry Analysis

Section 9: Industry SWOT Analysis

List of Figures

List of Tables

Companies Mentioned

- AbbVie

- Baliopharm

- Celgene

- Dutalys

- Eddingpharm

- Fabion Pharmaceuticals

- Ganymed Pharmaceuticals

- Ho Research Consortium

- ImClone System

- Janssen Biotech

- Krankenhaus Nordwest

- MacroGenics

- Nantes University Hospital

- OncoMed Pharmaceuticals

- Paktis Antibody Services GmbH

- Radboud University

- Sanofi

- Technische Universit√§t M√ľnchen

- University Hospital Tuebingen

- Xencor

- Zymeworks

and many more...

For more information visit http://www.researchandmarkets.com/research/v9bn9s/bispecific

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.